ArticleFrontiers in oncology2019
Enabling Precision Medicine for Rare Head and Neck Tumors: The Example of BRAF/MEK Targeting in Patients With Metastatic Ameloblastoma.
Article in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Malignant Odontogenic Tumours: A Systematic Review of Cases Reported in Literature.Frontiers in oral health · 2021Pooled it
- Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.Nature medicine · 2023Trial
- Oncogenic signaling pathways in ameloblastoma and their implications for precision based therapy.Discover oncology · 2026Review
- Comparative Performance Evaluation of GCN, GAT, and GraphSAGE Architectures for Drug-Gene Interaction Prediction in Ameloblastoma via MEK-Pathway Targeting.Asian Pacific journal of cancer prevention : APJCP · 2026Article
- Molecular-targeted therapy in ameloblastoma: a systematic review.Archives of craniofacial surgery · 2025Article
- Programmed death-ligand 1 regulates ameloblastoma growth and recurrence.International journal of oral science · 2025Article
- Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report.Rare tumors · 2025Article
- Histopathologic and Molecular Insights Following the Management of Ameloblastomas via Targeted Therapies - Pathological and Clinical Perspectives.Head and neck pathology · 2024Article
- Review
- Association of MDM2 Overexpression in Ameloblastomas withInternational journal of molecular sciences · 2024Article
- Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature.Heliyon · 2023Article
- Conventional Ameloblastoma. A Case Report with Microarray and Bioinformatic Analysis.Diagnostics (Basel, Switzerland) · 2022Article
- Review
- Precision medicine: Sustained response to erdafitinib in FGFR2-mutant, multiply recurrent ameloblastoma.Cancer reports (Hoboken, N.J.) · 2022Article
- Identification of BRAF V600E mutation in odontogenic tumors by high-performance MALDI-TOF analysis.International journal of oral science · 2022Article
- Precision drugging of the MAPK pathway in head and neck cancer.NPJ genomic medicine · 2022Review
- The Molecular Pathology of Odontogenic Tumors: Expanding the Spectrum of MAPK Pathway Driven Tumors.Frontiers in oral health · 2021Review
- Tomoelastography for non-invasive detection of ameloblastoma and metastatic neck lymph nodes.BMJ case reports · 2020Article
- Downregulated miR-524-5p Participates in the Tumor Microenvironment of Ameloblastoma by Targeting the Interleukin-33 (IL-33)/Suppression of Tumorigenicity 2 (ST2) Axis.Medical science monitor : international medical journal of experimental and clinical research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.